CRISPR-Cas CLINICAL TRIALS

All | TALEN | ZFN | MegaNuclease

Bacterial Infection

Urinary Tract Infections, UTI, (NCT04191148)
Open access


Sponsors:
Locus Biosciences
Indicator
IND Enabling
Phase I
Phase II
Phase III

Blood

Beta - thalassemia, BT, (NCT04205435)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia,
Sponsors:
Editas Medicine
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, (NCT03655678)
Sponsors:
Vertex Pharmaceuticals Incorporated
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT03728322)
Sponsors:
Allife Medical Science and Technology Co., Ltd
Indicator
IND Enabling
Phase I
Phase II
Phase III
Beta-thalassemia, BT, (NCT04211480)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
Human Immunodeficiency Virus Infection, HIV, (NCT03164135)
Sponsors:
Affiliated Hospital to Academy of Military Medical Sciences
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (EDIT-301)
Sponsors:
Editas Medicine 
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT03745287)
Sponsors:
Vertex Pharmaceuticals Incorporated
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT04443907)
Sponsors:
Novartis Pharmaceuticals
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT04774536)
Sponsors:
Principal Investigator: Mark Walters, MD UCSF Benioff Children's Hospital Oakland
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT04819841)
Sponsors:
Graphite Bio Inc
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion Dependent Beta-Thalassemia ,TDT, (NCT04390971)
Sponsors:
Institute of Hematology and Blood Diseases Hospital
IND Enabling
Phase I
Phase II
Phase III

Cancer

Acute Lymphoblastic Leukemia, ALL, (NCT04037566)
Sponsors:
Xijing Hospital, The Fourth Military Medical University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Acute Myeloid Leukaemia, AML
Sponsors:
Intellia Therapeutics
IND Enabling
Phase I
Phase II
Phase III
Acute Myeloid Leukaemia, AML, (NCT04614636)
Sponsors:
Fate Therapeutics, Inc
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
B Cell Malignancy, NHL, (NCT03166878)
Sponsors:
Chinese PLA General Hospital
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
B- cell Acute Lymphoblastic Leukemia, ALL, (NCT04557436)
Sponsors:
Great Ormond Street Hospital for Children NHS Foundation Trust
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-Cell Malignancies, NHL, (NCT04629729)
Sponsors:
Fate Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-cell Malignancy, NHL, (NCT04035434)
Sponsors:
CRISPR Therapeutics AG
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-cell Non-Hodgkin Lymphoma, NHL, (NCT04637763)
Sponsors:
Caribou Biosciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Esophageal Cancer, (NCT03081715)
Sponsors:
Hangzhou Cancer Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
Gastro-Intestinal Cancer, GI, (NCT04426669)
Sponsors:
Intima Bioscience, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Human papillomavirus (HPV) related cervical cancer, (NCT03057912)
Sponsors:
First Affiliated Hospital, Sun Yat-Sen University
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Multiple Myeloma, MM, (NCT03399448)
Sponsors:
University of Pennsylvania
Indicator
IND Enabling
Phase I
Phase II
Phase III
Multiple Myeloma, MM, (NCT03752541)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
Multiple Myeloma, MM, (NCT04244656)
Sponsors:
CRISPR Therapeutics AG
Indicator
IND Enabling
Phase I
Phase II
Phase III
Multiple Solid Tumor Adult, (NCT03545815)
Sponsors:
Chinese PLA General Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
Nasopharyngeal Carcinoma, (NCT03044743)
Sponsors:
Yang Yang, MD, PhD, MSCR, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, (NCT03229876)
Sponsors:
Bioray Laboratories - Shanghai Bangyao Biotechnology Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Malignancies, Non-Hodgkin lymphoma, NHL, (NCT04213469)
Sponsors:
Bioray Laboratories - Bangyao Biotechnology Co., Ltd. 
IND Enabling
Phase I
Phase II
Phase III
Relapsed refractory B- cell Acute Lymphoblastic Leukaemia, ALL, (2019-003462-40)
Sponsors:
Great Ormond Street Hospital for Children NHS Trust
Indicator
IND Enabling
Phase I
Phase II
Phase III
Relapsed/Refractory Haematopoietic Malignancies (NCT04767308)
Sponsors:
Huazhong University of Science and Technology
Indicator
IND Enabling
Phase I
Phase II
Phase III
Renal Cell Carcinoma, RCC, (NCT04438083)
Sponsors:
CRISPR Therapeutics AG
Indicator
IND Enabling
Phase I
Phase II
Phase III
Solid Tumor Adult, (NCT03747965)
Sponsors:
Chinese PLA General Hospital
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
T-Cell Chronic Lymphoblastic Leukaemia, CLL, (NCT04264078)
Sponsors:
Xinqiao Hospital of Chongqing
Indicator
IND Enabling
Phase I
Phase II
Phase III
T-Cell Lymphoma, (NCT04502446)
Sponsors:
CRISPR Therapeutics AG
Indicator
IND Enabling
Phase I
Phase II
Phase III

Eye

IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Leber Congenital Amaurosis, (NCT03872479)
Sponsors:
Editas Medicine, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III

Metabolic Disorders

close
Search CRISPR Medicine